Drug

New ALS Drug Wins FDA Approval Despite Questionable Data

New ALS Drug Wins FDA Approval Despite Questionable Data

WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won US approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines. The Food and Drug Administration approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in …

New ALS Drug Wins FDA Approval Despite Questionable Data Read More »

Nike shares fall, ALS drug approved and more: Friday's 5 things to know

Nike shares fall, ALS drug approved and more: Friday’s 5 things to know

Macro Trends Advisors LLC Founding Partner Mitch Roschelle and Former Trump senior economic adviser Steve Moore discuss tumbling stocks, large government deficits, lack of growth, and false signals on the market on ‘Cavuto: Coast to Coast’. Here are the key events taking place on Friday that could affect trading. NIKE RESULTS: Shares are down more …

Nike shares fall, ALS drug approved and more: Friday’s 5 things to know Read More »

ALS drug gets FDA approval despite uncertainty about effectiveness |  CNN

ALS drug gets FDA approval despite uncertainty about effectiveness | CNN

CNN — A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced the approval of Relyvrio, developed by Amylyx Pharmaceuticals, on Thursday. The oral medication can be taken as a standalone therapy or with other treatments, according to the company, and it has …

ALS drug gets FDA approval despite uncertainty about effectiveness | CNN Read More »

FDA approves first ALS drug in 5 years after pleas from patients

FDA approves first ALS drug in 5 years after pleas from patients

The Food and Drug Administration on Thursday overcame doubts from agency scientists and approved a fiercely debated drug for ALS, a move that heartened patients and advocates who pushed for the medication but raised concerns among some experts about whether treatments for dire conditions receive sufficient scrutiny. “It’s a huge deal,” said Sunny Brous, 35, …

FDA approves first ALS drug in 5 years after pleas from patients Read More »

Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say  CNN

Alzheimer’s drug slows progression of cognitive decline in clinical trial, drugmakers say CNN

CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary endpoints, showing “target engagement” with reduced amyloid levels – a protein that …

Alzheimer’s drug slows progression of cognitive decline in clinical trial, drugmakers say CNN Read More »

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

An experimental drug has slowed the rate of decline in memory and thinking in people with early Alzheimer’s disease in what is being described as a “historic moment” for dementia treatment. The cognition of Alzheimer’s patients given the drug, developed by Eisai and Biogen, declined by 27% less than those on a placebo treatment after …

Success of experimental Alzheimer’s drug hailed as ‘historic moment’ Read More »

Experimental Alzheimer's drug slows cognitive decline in trial, firm says

Experimental Alzheimer’s drug slows cognitive decline in trial, firm says

An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. Japanese drugmaker Eisai and its American partner, Biogen, in a news release said the slowing of deterioration, compared …

Experimental Alzheimer’s drug slows cognitive decline in trial, firm says Read More »

Eisai, Biogen says Alzheimer's drug succeeds in slowing cognitive decline

Eisai, Biogen says Alzheimer’s drug succeeds in slowing cognitive decline

Sept 27 (Reuters) – Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) on Tuesday said their experimental Alzheimer’s drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs. The drug, lecanemab, slowed the progress …

Eisai, Biogen says Alzheimer’s drug succeeds in slowing cognitive decline Read More »

Pfizer CEO Bourla has tested positive for Covid for the second time in a month.  Pictured: about to testify on drug prices before the Senate Finance Committee, on Capitol Hill in Washington in February 2019

Pfizer boss tests positive for Covid for second time in a MONTH – amid drug giant’s booster rollout

Quadruple-vaccinated Pfizer boss, 60, tests positive for Covid for the second time in a MONTH Pfizer CEO has tested positive for Covid for the second time since mid-August He has had four vaccines but is yet to receive Pfizer’s autumn bivalent booster It comes after President Joe Biden said last week ‘the pandemic is over’ …

Pfizer boss tests positive for Covid for second time in a MONTH – amid drug giant’s booster rollout Read More »

Hollywood's Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic

Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic

Last week’s Emmy awards saw big winners gush with gratitude over their agents, managers, and audiences, but there was one notable benefactor to many stars that went unthanked: the injectable drug semaglutide, whose brand name is Ozempic. The drug is an insulin regulator for the pre-diabetic, made by the Danish pharma juggernaut Novo Nordisk, whose …

Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic Read More »